NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.15 (-0.19%) GOLD FUTURES
2,431.70 -6.80 (-0.28%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,801.49 +2,605.08 (+4.99%)
NVO Jan 2025 175.000 put
| Previous close | 45.70 |
| Open | 45.70 |
| Bid | 40.35 |
| Ask | 43.00 |
| Strike | 175.00 |
| Expiry date | 2025-01-17 |
| Day's range | 45.70 - 45.70 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Barrons.comHims & Hers Stock Spikes. It’s Taking on Big Pharma With Cheap Obesity Shots.
A relatively small telehealth company that recently went public wants to take a slice of the big pharmaceuticals companies’ hottest market. Hims & Hers Health said on Monday that it is offering weight-loss injections for as low as $199 a month, a move that capitalizes on the growing demand for such treatments. The telehealth platform started offering oral medication kits for weight loss late last year and is now expanding its roster of products as it seeks to compete with companies like Eli Lilly and Novo Nordisk.
BenzingaGenetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide). The study, presented at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients with this genetic profile would be strong responders to the treatment. Related: Changing Frugal Eating Habits-How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending. Th
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
